Intellipharmaceutics CEO moulded at Biovail U
June 22, 2010 by leonardzehr · Leave a Comment
Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]
Listen to BioTuesdays 
